Method for acquiring bioactive proteins by utilizing umbilical cord mesenchymal stem cells

Abstract

The invention discloses a method for acquiring bioactive proteins by utilizing umbilical cord mesenchymal stem cells. The method comprises the following steps: digesting Wharton's jelly of umbilical cord in short time by using type I collagenase, thereby obtaining a paste mixture containing extracellular matrix proteins and tissue blocks; performing primary culture; adding a stem cell growth culture medium into a packed bed type bioreactor for amplifying the umbilical cord mesenchymal stem cells; adding a protein production culture medium for performing continuous culture when the cell fusion rate in the reactor reaches the standard; collecting the culture solution, and treating the solution, thereby obtaining the bioactive proteins. According to the method for acquiring the bioactive proteins by utilizing umbilical cord mesenchymal stem cells disclosed by the invention, the purity of the obtained umbilical cord mesenchymal stem cells is high, the multiplication capacity is high, and the stem cell culture time is shortened; and moreover, the yield of the obtained bioactive proteins is high, the quality control process is convenient, and large-scale production is easily realized. The stem cells and bioactive proteins do not contain animal source components, and the safety of clinical application is improved.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a method for obtaining biologically active proteins by using umbilical cord mesenchymal stem cells. Background technique [0002] Mesenchymal stem cells (Mesenchymal stem cells) are a type of adult stem cells with multi-directional differentiation potential. obtained from various organizations. Mesenchymal stem cells are non-terminal differentiated cells, which have both the characteristics of mesenchymal cells and the characteristics of endothelial cells and epithelial cells; as a type of pluripotent stem cells, they can develop into bone, Cartilage, muscle, tendon, liver, fat, nerve, endothelial and islet-like cells proliferate and differentiate. Currently known to have certain therapeutic effects on myocardial infarction, diabetes, osteoporosis, osteonecrosis, lupus nephritis, liver cirrhosis, liver failure, multiple cirrhosis, systemic lupus erythematosus, Parkinson's disease, ...

AI Technical Summary

Problems solved by technology

Using bioreactors to cultivate cells to obtain bioactive proteins to meet the needs of clinical applications is a major trend in the production of stem cells and bioactive proteins, but there are many shortcomings in practical applications: patent CN101985612A uses microcarriers in culture bags For large-scale culture of adherent cells, there are disadvantages that the cells are easy to settle and the state of the culture medium is not easy to monitor

Developed countries such as the United States and the European Union have completely stopped using serum in biopharmaceuticals as early as 2010. If you continue to use serum to cultivate cells and use trypsin to digest cells, the introduction of animal sources into cells and bioactive proteins will increase. The risk of sexual components reduces the safety of its clinical application

Images